The CSL Limited (ASX: CSL) share price is climbing higher today on news that the global biotech giant will be building a manufacturing facility in Australia.
The CSL share price kicked off the day reaching as high as $315.85. However, before the ASX experienced a technical glitch which halted market trade, CSL shares slightly retreated to $315.04, up 1.8%.
What is driving the CSL share price?
CSL advised that its subsidiary, Seqirus, plans to invest more $800 million in the construction of an influenza vaccine manufacturing facility.
Based in Melbourne, the state-of-the-art factory will produce and supply flu vaccines to Australia and the rest of the world. The decision follows a deal with the Federal Government for a range of life-saving treatments to the Australian population for over 10 years. This includes anti-venoms for Australian snakes, spiders and marine creatures, and influenza pandemic protection.
Under the terms of the deal, the Morrison government will contribute $1 billion over 12 years along with CSL’s Seqirus investment. The Victorian Government is also expected to commit to the project but has yet to announce a support package.
The new facility will be built at a site in the Melbourne Airport Business Park, with construction to start in 2021. Housing innovative cell-based technology to produce these critical vaccines, CSL will also manufacture Seqirus’ MF59 substance. The latter is a formula that is added to improve immune response and reduce the amount of antigen needed for each vaccine.
Final completion is projected to be around mid-2026, with the facility becoming fully operational.
What did the head of CSL say?
Commenting on the opportunity, CSL CEO and managing director Paul Perreault said:
Providing safe and effective influenza vaccines is essential in securing our defences against serious public health threats.
The facility will be an important addition to our global influenza manufacturing supply chain, incorporating the technology platform used in our Holly Springs, North Carolina facility. Cell-influenza vaccine technology offers many advantages over the existing process including being more scalable and offering faster production – particularly important in the case of influenza pandemics.
As a proudly Australian company, we are pleased to make this investment in world- class advanced manufacturing. This decision will ensure the future of 1,000+ Science Technology Engineering & Manufacturing jobs in Victoria and a supply chain of more than $300 million annually.
About the CSL share price
The CSL share price has been on a mini-rollercoaster ride over the past 6 months. Besides reaching today’s new high since May, shares in the biotech company have been up and down alongside COVID-19 and economic impacts.
As Australia largest company, CSL has a market capitalisation of $143.3 billion and a price-to-earnings (P/E) ratio of 68.2.
Our TOP healthcare stock is trading at a 30% discount to its highs
If there’s one thing for sure, 2020 has been the year we embraced sanitisation. Scott Phillips has discovered a little-known Australian healthcare company could be set to reap the rewards of the post-covid world.
Better yet, this fast-growing company is currently trading at a 30% discount from its highs. Scott believes in this stock so much, he’s staked $209k of our own company money on it. Forget ‘buy now pay later’, this stock could be the next hot stock on the ASX.
Scott and his team have published a detailed report on this tiny ASX stock. Find out how you can access our TOP healthcare stock today!
Find out the name of this stock
As of 2.11.2020
More reading
- ASX 200 up 1.2%: Afterpay ASIC response, Elders result, CSL vaccine facility
- ASX 200 Weekly Wrap: ASX continues to hit post-COVID highs
- How to get rich with ASX dividend shares
- 3 fantastic ASX shares to buy next week
- After 8 months, ASX 200 shares are finally out of correction territory
Aaron Teboneras owns shares of CSL Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post Why the CSL (ASX: CSL) share price is climbing higher today appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/3f1KU9n
Leave a Reply